Skip to main navigation Skip to search Skip to main content

Can we navigate the pitfalls of tofacitinib randomized controlled trials in vitiligo? Addressing long-term safety and generalizability for enhanced clinical translation

  • Canni Gao
  • , Xinxin Duan
  • , Leixuan Peng
  • , Pan Li
  • , Kuanhou Mou
  • The First Affiliated Hospital of Xi’an Jiaotong University

Research output: Contribution to journalLetterpeer-review

Original languageEnglish
JournalJournal of the American Academy of Dermatology
DOIs
StateAccepted/In press - 2026
Externally publishedYes

Keywords

  • drug safety
  • JAK inhibitors
  • safety and risk-benefit balance
  • study population generalizability
  • vitiligo

Cite this